ReviewBioinorganic chemistry and applications2026
ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.
Review in Bioinorganic chemistry and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The successful clinical use of metal-based anticancer agents depends heavily on a detailed understanding of their absorption, distribution, metabolism, excretion, and toxicology (ADMET) profiles. This review evaluates the ADMET properties of anticancer complexes involving platinum, palladium, gold, ruthenium, copper, and zinc. Unlike traditional organic medicines, the ADMET processes of these compounds are often complex and nonlinear, due to their unique coordination chemistry, ligand-exchange kinetics, and dynamic speciation changes. The review highlights how structural differences in metal analogs influence their pharmacokinetics, systemic disposition, and distinct toxicity profiles. Ultimately, gaining a thorough understanding of these ADMET nuances is vital for designing next-generation metallodrugs with optimized tissue distribution, minimal systemic toxicity, and improved therapeutic effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.